Registration Options

Register for the meeting and/or this session. (Additional registration required)

Session Time and Location

Date: Sunday, 04/24/2022

Time: 8:00 AM (view in the schedule)

Room: TBD

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

Individuals with severe mental illness (SMI), such as schizophrenia, bipolar disorder and depression, have an elevated risk of cardiovascular disease (CVD). In addition to the increased prevalence of modifiable risk factors in these populations, many of the medications used in disease management have been linked to weight gain and/or worsening of metabolic cardiovascular risks. Pharmacists are often an underutilized health care resource despite their medication expertise and accessibility. As frontline clinicians, psychiatric pharmacists are trained in the detection and ongoing monitoring of various cardiovascular comorbidities, and are frequently the first to identify such problems. When pharmacists partner with prescribers they are able to take the lead in developing treatment plans, communicating with patients, improving adherence, monitoring patients, identifying treatment options, and performing tasks to alleviate prescriber burden.

This session will demonstrate different practice settings where psychiatric pharmacists partner with prescribers to provide collaborative care for metabolic disorders in patients with comorbid mental illness. The learner will leave with updated knowledge of current practice standards and treatment strategies for managing comorbid CVD. Furthermore, they will gain a better understanding of how to incorporate this knowledge into routine practice through the practical application in real-life case scenarios.

Agenda

  • 8:00-8:10 AM: Welcome and introductions
  • 8:10-8:35 AM: Key guidelines and assessment tools
  • 8:35-9:00 AM: Small group case evaluation and reporting: Guideline application and determining if intervention is warranted for the primary prevention CVD while considering psychiatric illness
  • 9:00-9:10 AM: Break
  • 9:10-9:35 AM: Standard treatment approaches and clinical pearls for drug selection in secondary prevention CVD patients
  • 9:35-10:00 AM: Small group case evaluation and reporting: Appropriate treatment selection and level of intervention while considering psychiatric illness in a secondary prevention CVD patient
  • 10:00-10:10 AM: Break
  • 10:10-10:35 AM: Optimization and ongoing monitoring in vulnerable patient populations
  • 10:35-11:00 AM: Small group case evaluation and reporting: Optimizing treatment and therapeutic goals in vulnerable populations while considering psychiatric illness
  • 11:00-11:15 AM: Q&A

Faculty Information and Disclosures

Sarah Anderson PharmD, BCACP, BCPS, FASHP, FCCP
Joel C. Marrs, PharmD, MPH, BCACP, BCCP, BCPS, CHC, CLS, FAHA, FASHP, FCCP, FNLA

View biographical information and disclosures

Learning Objectives

  1. Review key recommendations from essential guidelines for the management of common cardiovascular diseases (CVDs).
  2. Apply various risk assessment tools to determine which patients require intervention.
  3. Describe current pharmacologic approaches for the management of CVD in a patient with mental illness.
  4. Identify strategies to achieve optimal outcomes in patients with CVD and mental illness.
  5. Select an appropriate monitoring plan for a patient with CVD to determine if treatment goals are being met.

Continuing Education Credit and Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.